• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BIOA
Held by 1 Guru
Share

BioAge Labs, Inc. Stocks

$ 11.72Last Updated 07.08.2026

Issuer Rating

2/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 441.25M

$ 11.72
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

23.10.2025 16:11

Citigroup upgrades rating, TP on obesity drugmaker BioAge amid upcoming clinical data

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of BIOA is 35.5 and suggests 203% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.08.2026 17:47

Analysts have predicted renewed growth in the European defense sector. Which stocks will benefit?

11.08.2026 17:25

Mid-cap biotech stocks soared on the back of successful trials of a hot flash treatment

11.08.2026 16:55

The price of gold rose above $4,400. Citadel identified a rare combination of factors driving the rise

11.08.2026 16:30

Biotech firm Sionna unexpectedly failed its drug trials and lost 90% of its value in a single day

11.08.2026 16:08

Brent crude has approached $90. An analyst warned of the risk of a price spike as early as next week

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026